thapsigargin and Hyperplasia

Coronary artery bypass graft surgery (CABG) is widely used for the treatment of atheromatous stenosis of coronary arteries. However, as many as 50% of grafts fail within 10 years after CABG due to neointima (NI) formation, a process involving the proliferation and migration of vascular smooth muscle cells (VSMCs). Superimposed on neointima formation is accelerated atherogenesis which ultimately results in late vein graft failure. To date no therapeutic intervention has proved successful in treating late vein graft failure and as such is a matter of some urgency. However, in recent years, several diverse approaches aimed at preventing neointimal formation have been devised which have yielded promising results. These include the use of external stents, gene therapy as well as conventional pharmacological interventions. The objective of this article, therefore, is to review these recent approaches and their potential clinical applications in the treatment of vein graft disease.

Topics: Animals; Calcium-Transporting ATPases; Coronary Artery Bypass; Coronary Stenosis; Enzyme Inhibitors; Genetic Therapy; Humans; Hyperplasia; Models, Animal; Muscle, Smooth, Vascular; Saphenous Vein; Swine; Thapsigargin; Transplantation, Autologous; Treatment Failure; Tunica Intima

In estrogen-induced pituitary hyperplasia AII-evoked prolactin release is decreased and the octapeptide does not generate a spike elevation in [Ca(2+)](i) in vitro. We studied whether or not bromocriptine could restore AII response in diethylstilbestrol treated rats. Co-administration of bromocriptine resulted in involution of pituitary size and lowering of serum prolactin. In vitro, prolactin release per cell was reduced in the hyperplastic group, and levels were not significantly increased by in vivo bromocriptine treatment. Immunocytochemical analysis revealed that hyperplastic pituitaries contained fewer prolactin granules than control pituitaries, and that bromocriptine, did not increase prolactin storage. Nevertheless, in this group, prolactin response to AII increased, and AII evoked a consistent spike in [Ca(2+)](i), albeit lower than in the control group. Such spike was abolished by thapsigargin, and not by removal of extracellular calcium or by K(+), indicating that it was mainly dependent on intracellular calcium stores, as in normal cells. We conclude that bromocriptine treatment partially restores AII response in the hyperplastic pituitary.

Topics: Angiotensin II; Animals; Bromocriptine; Calcium; Calcium Channels; Diethylstilbestrol; Female; Hyperplasia; Immunohistochemistry; In Vitro Techniques; Pituitary Gland; Potassium; Prolactin; Rats; Rats, Sprague-Dawley; Thapsigargin

Interleukin-1 receptor antagonist (IL-1Ra) is an endogenous inhibitor of interleukin-1. The expression of IL-1Ra and interleukin-1alpha (IL-1alpha) was measured in murine epidermis after treatment with tumor promoters and in tumor cell lines. A single treatment with three different tumor promoters (12-O-tetradecanoylphorbol-13-acetate (TPA), anthralin, and thapsigargin) induced IL-1Ra mRNA with different kinetics in mouse skin. The expression of IL-1Ra mRNA also was induced by TPA and IL-1alpha in a dose-related and time-dependent manner in cultured mouse keratinocytes. Expression of IL-1Ra mRNA peaked 6 h after treatment. Both IL-1Ra and IL-1alpha protein and IL-1Ra and IL-1alpha mRNA were measured in various keratinocyte tumor cell lines (C50, MT1/2, HEL30, JWF2, CH72, and BPCC2). The expression of IL-1alpha was increased in papilloma and squamous cell carcinoma cell lines. IL-1Ra protein also was increased in nontumorigenic and papilloma cell lines; however, the expression was dramatically reduced in some carcinoma cell lines. Finally, we detected IL-1alpha and IL-1Ra protein in mouse skin tumors by western blot analysis, and localization was assessed by immunohistochemical analysis. Positive staining for both IL-1alpha and IL-1Ra was observed in the cytoplasm and was most prominent in the suprabasal layer. Although IL-1Ra protein increased in papillomas and carcinomas, IL-1alpha protein was not significantly increased above basal level in most tumors.

Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anthralin; Blotting, Northern; Blotting, Western; Carcinogens; Carcinoma, Squamous Cell; Cell Polarity; Cytoplasm; Disease Progression; Epidermis; Gene Expression Regulation, Neoplastic; Hyperplasia; Inflammation; Interleukin 1 Receptor Antagonist Protein; Interleukin-1; Keratinocytes; Mice; Mice, Inbred SENCAR; Neoplasm Proteins; Papilloma; Precancerous Conditions; RNA, Messenger; RNA, Neoplasm; Sialoglycoproteins; Skin Diseases; Skin Neoplasms; Tetradecanoylphorbol Acetate; Thapsigargin; Tumor Cells, Cultured

In rat pituitary cells from estrogen-induced hyperplasia, angiotensin II (ANG II) does not evoke a clear spike elevation of intracellular Ca2+ concentration ([Ca2+]i) but induces a plateau increase. The present work was undertaken to establish whether this difference was related to a differential participation of intracellular and/or plasma membrane Ca2+ channels. We first tested the effect of 10 nM ANG II on [Ca2+]i in the absence of extracellular Ca2+ in cells depolarized with 25 mM K+ or in the presence of blockers of L-type voltage-sensitive Ca2+ channels (VSCC). These treatments did not alter spike elevation in [Ca2+]i in controls but reduced plateau levels in hyperplastic cells. Intracellular Ca2+ stores were similar in both groups, as assessed by thapsigargin treatment, but this drug abolished spike increase in controls and scarcely modified plateau levels in hyperplastic cells. Finally, inositol trisphosphate (InsP3) production in response to ANG II was significantly higher in control cells. We conclude that the observed plateau rise in hyperplastic cells results mainly from Ca2+ influx through VSCC. In contrast, in control cells, the ANG II-induced spike increase in [Ca2+]i results from mobilization of Ca2+ from thapsigargin-sensitive internal channels, activated by higher inositol 1,4,5-trisphosphate generation.

Topics: Angiotensin II; Animals; Calcium; Calcium Channel Blockers; Calcium Channels, L-Type; Female; Hyperplasia; Inositol 1,4,5-Trisphosphate; Intracellular Membranes; Pituitary Gland; Potassium; Rats; Rats, Sprague-Dawley; Reference Values; Thapsigargin

Thapsigargin (Tg), applied twice weekly to the backs of CD-1 mice initiated with 7,12-dimethylbenz[a]anthracene, promoted papillomas on the skin of approximately 50% of the mice. Tg alone induced papillomas in 10% of the mice. Although Tg and 12-O-tetradecanoylphorbol-13-acetate (TPA) are synergistic in a keratinocyte co-culture assay for promotion, skin tumor promotion by TPA was inhibited by co-treatment with Tg. Treatment of cultured keratinocytes with non-toxic doses of Tg increased the level of intracellular free Ca(2+)-induced stratification. Tg blocked expression of the spinous layer differentiation marker keratin 1 (K1), while inducing cornification, a marker of differentiation in the granular layer/stratum corneum. In medium with 1.4 mM Ca2+, Tg prolonged keratinocyte proliferation and selected foci of monolayer cells. A Tg-independent cell line, TK-1, was developed from a single dish in which foci continued to expand after Tg removal. Grafting TK-1 cells on to the backs of nude mice as part of a reconstituted skin resulted in the development of dysplastic papillomas with a high rate of progression to squamous cell carcinomas.

Topics: Animals; Calcium; Carcinogens; Cell Differentiation; Cell Division; Cells, Cultured; Drug Synergism; Female; Hyperplasia; Keratinocytes; Mice; Phenotype; Skin; Skin Neoplasms; Terpenes; Tetradecanoylphorbol Acetate; Thapsigargin

The effect of thapsigargin (Tg), a non-12-O-tetradecanoylphorbol-13-acetate (TPA) type skin tumor promoter, on arachidonic acid and prostaglandin E2 (PGE2) formation in HEL30 keratinocytes and on epidermal DNA synthesis in vitro and in vivo (mouse skin) was investigated and compared with that of the phorbol ester TPA. On a molar basis Tg was 30-fold more potent in inducing the arachidonic acid/PGE2 release than TPA. Applied together, the two agents showed a strong synergistic action. The response critically depended on the presence of Ca2+ in the extracellular medium. While the TPA-induced release was mediated by protein kinase C (PKC) the Tg-induced release was not. In contrast to TPA (1 microM), which is a stimulator of HEL30 DNA synthesis, Tg (0.1-1 microM) inhibited DNA labeling in vitro due to a pronounced cytotoxic effect. TPA did not exhibit such an effect. In vivo both agents were practically equipotent in inducing epidermal DNA synthesis and hyperplasia with TPA having an approximately 10-fold higher irritating potential than Tg. It is concluded that the hyperplasiogenic and tumor-promoting effect of Tg in vivo is due to cytotoxicity causing cell death and regenerative hyperproliferation. Thus, Tg-induced skin tumor promotion seems to resemble tumor promotion by mechanical skin wounding, whereas TPA evokes a more specific, i.e. PKC-mediated response. Since despite these mechanistic differences both agents induce an immediate release of arachidonic acid/PGE2 in keratinocytes, this response may be considered to provide an in vitro parameter for irritancy and tumor promotion.

Topics: Animals; Arachidonic Acid; Arachidonic Acids; Cell Division; Cell Line; Female; Hyperplasia; Keratinocytes; Mice; Skin; Terpenes; Tetradecanoylphorbol Acetate; Thapsigargin